Sorrento Therapeutics Inc (SRNE)

[dia76ca]

1776...while discussing ZTlido...Paul commented,
"ZTlido made $40M+ in a chaotic year with the pandemic while others stumbled, and if I’m correct Ji mentioned going forward they expect around $100M revenue annually.

Add that to shares in ImmuneOncia, Celularity, and ImmunityBio plus everything else Sorrento has on their plate, and they have enough cash on hand for trials for several years. But with the approval of SP102, Abivertinib, and RTX all sometime this year or next, I think Sorrento is doing just fine. Let’s toss in a couple of EUA’s, say Abivertinib (covid), MSC, and STIX in near future while where at it."